Targets › ADA
3 programs from 3 companies in 4 trials: 3 Phase 2, 1 Phase 1; Hematology, Infectious disease, Oncology; next expected readout Jun 2027.
Catalyzes the hydrolytic deamination of adenosine and 2-deoxyadenosine. Plays an important role in purine metabolism and in adenosine homeostasis. (UniProt, P00813)
Open in Phaseline: the race on ADA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | Pentostatin Adenosine deaminase inhibitor | ADA | Phase 2 | Sickle Cell Disease | Dec 2027 |
| National Cancer Institute (NCI) | Pentostatin Adenosine deaminase inhibitor | ADA | Phase 2 | Hairy Cell Leukemia; Primary T-cell Immunodeficiency Disorders | Jun 2031 |
| City of Hope Medical Center | Pentostatin Adenosine deaminase inhibitor | ADA | Phase 1 | Recurrent Severe Aplastic Anemia | Jun 2027 |
Hairy Cell Leukemia (1) Primary T-cell Immunodeficiency Disorders (1) Recurrent Severe Aplastic Anemia (1) Sickle Cell Disease (1)
mixed (3)
National Cancer Institute (NCI) (1) City of Hope Medical Center (1) National Heart, Lung, and Blood Institute (NHLBI) (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.